Press Releases

Noverra Research Analysts Issue Watch List Report on Cynapsus Therapeutics

Marketwire, December 28, 2021


TORONTO, CANADA – Cynapsus Therapeutics advises that Noverra Research, a provider of independent equity research, has released a comprehensive report that describes Cynapsus’ business along with its recommendations. This 10-page report includes detailed information about the Parkinson’s disease market, Cynapsus’ APL-130277 project and strategy, as well as other company-related information and associated risks.

Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson’s disease. Parkinson’s disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. It is estimated that between 25 percent and 50 percent of patients experience “off episodes” in which they have impaired movement or speaking capabilities. Current medications only control the disease’s symptoms, and most drugs become less effective over time as the disease progresses.

Cynapsus’ lead drug candidate, APL-130277, is an easy-to-administer, fast-acting and oral reformulation of an approved drug, apomorphine, used to rescue patients from off episodes. Cynapsus is focused on rapidly maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application expected to be submitted in 2013 or 2014. The Company anticipates out-licensing to an appropriate pharmaceutical partner before such an application is submitted.

More information about Cynapsus (CTH: TSX-V) is available at www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

For a free copy of the full research report, please visit www.noverraresearch.com.

Company Notice on Noverra Research

Any opinions, judgments, estimates, or forecasts regarding Cynapsus’ historical or predicted performance or operations made by Noverra Research are its alone. Cynapsus does not by its reference to the research prepared by Noverra Research imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.

Contact Information

Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
[email protected]

Andrew Williams
COO & CFO
(416) 703-2449 x253
[email protected]

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of applicable Canadian securities legislation. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Cynapsus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks and uncertainties relating to Cynapsus’ business disclosed under the heading “Risk Factors” in Cynapsus' current Annual Information Form and its other filings with the various Canadian securities regulators which are available online at www.sedar.com. Although Cynapsus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cynapsus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.

--30--

Horizonatal Rule
  About CynapsusLine SeperationValue PropositionLine SeperationAPL-130277 ProductLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2012, Cynapsus Therapeutics Inc. All rights reserved.